International Alliance for Personalised Medicine (IAPM) shared a post on LinkedIn:
“The Real Question About Oral SERDs Is No Longer Whether They Work.
It is where they belong.
At ASCO2026, new data on giredestrant highlighted both the promise and the complexity of oral SERDs in ER-positive, HER2-negative breast cancer. Positive signals emerged in some settings, while other results reinforced a reality that precision oncology continues to face: success is rarely universal. It is often highly dependent on timing, biology, and patient selection.
This is why the conversation cannot be reduced to whether a new therapy is ‘good’ or ‘bad.’
The more important questions are:
- Which patients benefit most?
- At what stage of disease?
- How should treatment be sequenced alongside CDK4/6 inhibitors, targeted therapies, and ADCs?
- What evidence will payers and health systems require before broad adoption?
For healthcare systems, this is not simply a drug story. It is an implementation story.
Precision medicine succeeds when innovation is matched with evidence, diagnostics, clinical pathways, and reimbursement strategies that place the right treatment with the right patient at the right time.
As oral SERDs continue to evolve, the challenge is no longer scientific enthusiasm.
It is evidence discipline.
Because in personalised medicine, where a therapy fits can matter just as much as whether it works.
Read IPM full analysis”
Other articles about IAPM on OncoDaily.